Clinical Trial

Impact of Vericiguat on Hemodynamics of Heart Failure

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for patients with heart failure. In a large randomized controlled trial, this drug was found to help patients with heart failure live longer and stay out of the hospital more than normal treatment for heart failure. However, it is unclear how this drug positively impacts "hemodynamics", meaning how the heart functions during activity/exercise, and how it may also help blood pressure and health of the blood vessels and autonomic nervous system. This study, funded by the drug manufacturer, Merck Corp, will enroll 30 patients with heart failure. The patients will undergo baseline testing, and then be randomized to either receive vericiguat or a placebo for about three months, and then come back for follow-up testing to learn more about how the drug impacts heart function.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-19; most recent amendment 2025-11-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-11
Trial Details
NCT Number NCT05704478
Lead Sponsor University of Colorado, Denver
Conditions Heart Failure
Enrollment 30 participants
Start Date 2024-01-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-13